GSK’s Head Of Artificial Intelligence Unveils R&D Goals
GSK’s John Baldoni talks to Scrip in an exclusive interview about taking over the big pharma’s artificial intelligence R&D strategy and the company’s early-stage progress using machine-driven discovery and development methods.
You may also be interested in...
BI and Epizyme’s collaboration will focus on developing novel cancer drugs targeting helicase and HAT enzyme dysregulation. MorphoSys and I-Mab will partner on developing an IO therapy targeting C5aR.
A selection of articles you might have missed from July 2020, including exclusive interviews with industry leaders and a review of Q2 financing statistics.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.